Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Sony Group Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.67 (market cap $39.89B), while Sony Group Corp trades at $20.8 (market cap $121.92B). The key difference: Sony Group Corp is far larger — about 3.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Sony Group Corp pays a 0.76% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SONY | |
|---|---|---|
Market Cap | $39.89B | $121.92B |
Sector | Health | Technology |
52-Week High | $491.22 | $30.26 |
52-Week Low | $278.09 | $19.32 |
Enterprise Value | $38.15B | $118.41B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Sony trades at $20.85, down 0.38% on the day, with a neutral technical signal. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company reported strong operating cash flow of $2.32 trillion in 2025, though net income margin remains negative at -2.62%. Key news includes Sony's plan to phase out PlayStation physical discs by 2028 and conditional approval for a U.S. stablecoin bank.
Outlook is cautiously optimistic with 69% analyst buy ratings, but risks include execution of digital transition and projected negative net income in 2026. The stock's valuation appears reasonable with a P/E of 19.68, but investors should monitor earnings consistency and market reception to strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
